drugset / Trial / NCT02773576

Safety and Tolerability of Risperidone Implants

NCT02773576

Phase 3 Completed 140 enrolled Braeburn Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia

Timeline

Start
2016-04
Primary completion
2017-09
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 300 mg
Subject Risperidone Other / unclassified 360 mg

Indications